Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters











Publication year range
1.
Gene Ther ; 22(1): 9-19, 2015 Jan.
Article in English | MEDLINE | ID: mdl-25410742

ABSTRACT

Secreted protein, acidic and rich in cysteine (SPARC) is involved in many biological process including liver fibrogenesis, but its role in acute liver damage is unknown. To examine the role of SPARC in acute liver injury, we used SPARC knock-out (SPARC(-/-)) mice. Two models of acute liver damage were used: concanavalin A (Con A) and the agonistic anti-CD95 antibody Jo2. SPARC expression levels were analyzed in liver samples from patients with acute-on-chronic alcoholic hepatitis (AH). SPARC expression is increased on acute-on-chronic AH patients. Knockdown of SPARC decreased hepatic damage in the two models of liver injury. SPARC(-/-) mice showed a marked reduction in Con A-induced necroinflammation. Infiltration by CD4+ T cells, expression of tumor necrosis factor-α and interleukin-6 and apoptosis were attenuated in SPARC(-/-) mice. Sinusoidal endothelial cell monolayer was preserved and was less activated in Con A-treated SPARC(-/-) mice. SPARC knockdown reduced Con A-induced autophagy of cultured human microvascular endothelial cells (HMEC-1). Hepatic transcriptome analysis revealed several gene networks that may have a role in the attenuated liver damaged found in Con A-treated SPARC(-/-) mice. SPARC has a significant role in the development of Con A-induced severe liver injury. These results suggest that SPARC could represent a therapeutic target in acute liver injury.


Subject(s)
Chemical and Drug Induced Liver Injury/metabolism , Endothelial Cells/physiology , Osteonectin/genetics , Animals , Chemical and Drug Induced Liver Injury/immunology , Concanavalin A , Endothelium, Vascular/pathology , Gene Knockdown Techniques , Lipopolysaccharides/pharmacology , Liver , Male , Mice, 129 Strain , Mice, Inbred C57BL , Mice, Knockout , Osteonectin/metabolism , Transcriptome
2.
Gene Ther ; 17(6): 692-708, 2010 Jun.
Article in English | MEDLINE | ID: mdl-20220785

ABSTRACT

Mesenchymal stem (stromal) cells (MSCs) are a source of circulating progenitors that are able to generate cells of all mesenchymal lineages and to cover cellular demands of injured tissues. The extent of their transdifferentiation plasticity remains controversial. Cells with MSC properties have been obtained from diverse tissues after purification and expansion in vitro. These cellular populations are heterogeneous and under certain conditions show pluripotent-like properties. MSCs present immunosuppressive and anti-inflammatory features and high migratory capacity toward inflamed or remodeling tissues. In this study we review available data regarding factors and signaling axes involved in the chemoattraction and engraftment of MSCs to an injured tissue or to a tissue undergoing active remodeling. Moreover, experimental evidence in support of uses of MSCs as vehicles of therapeutic genes is discussed. Because of its regenerative capacity and its particular immune properties, the liver is a good model to analyze the potential of MSC-based therapies. Finally, the potential application of MSCs and genetically modified MSCs in liver fibrosis and hepatocellular carcinoma (HCC) is proposed in view of available evidence.


Subject(s)
Carcinoma, Hepatocellular/therapy , Genetic Therapy , Liver Cirrhosis/therapy , Liver Neoplasms/therapy , Mesenchymal Stem Cells , Animals , Chemotaxis , Gene Transfer Techniques , Genetic Engineering , Mesenchymal Stem Cells/immunology , Mesenchymal Stem Cells/physiology , Mice
SELECTION OF CITATIONS
SEARCH DETAIL